Kairos Pharma Ltd's Comment on Sales, Marketing and Customers
The company focuses on cancer patient populations with tumors that develop resistance to standard therapies, specifically targeting non-small cell lung cancer, prostate cancer, and glioblastoma. It has initiated clinical trials for ENV 105 in non-small cell lung cancer and prostate cancer. A Phase 2 trial for prostate cancer was conducted at Cedars-Sinai Medical Center involving heavily pre-treated patients, utilizing standard hormone therapies enzalutamide (Xtandi®, Pfizer) and abiraterone (ZYTIGA®, Janssen). The company also addresses chemotherapy resistance and cachexia in cancer patients. Its drug portfolio includes immunotherapeutics and therapeutic agents targeting large markets such as prostate cancer, valued at USD 7.9 billion, and EGFR mutant non-small cell lung cancer, valued at USD 1.7 billion. Additionally, KROS 201 is developed for the treatment of glioblastoma. Customers and collaborators mentioned include Cedars-Sinai Medical Center, Janssen, and Pfizer.
In the rapidly evolving landscape of oncology, precision medicine stands out as a beacon of hope for enhancing treatment outcomes. An exciting development emerged with Kairos Pharma Ltd. s recent agreement with PreCheck Health Services Inc. This partnership focuses on the development of biomarkers to identify patients most likely to respond to ENV105, a targeted therapy aimed at combatting drug resistance in prostate and lung cancer patients. This article outlines the implications of this collaboration for the future of cancer treatment and highlights the importance of advancing precision healthcare. The Need for Precision in Cancer Treatment Cancer remains one of the leading causes of morbidity and mortalit...
Kairos Pharma Ltd’s Comment on Sales, Marketing and Customers
The company focuses on cancer patient populations with tumors that develop resistance to standard therapies, specifically targeting non-small cell lung cancer, prostate cancer, and glioblastoma. It has initiated clinical trials for ENV 105 in non-small cell lung cancer and prostate cancer. A Phase 2 trial for prostate cancer was conducted at Cedars-Sinai Medical Center involving heavily pre-treated patients, utilizing standard hormone therapies enzalutamide (Xtandi®, Pfizer) and abiraterone (ZYTIGA®, Janssen). The company also addresses chemotherapy resistance and cachexia in cancer patients. Its drug portfolio includes immunotherapeutics and therapeutic agents targeting large markets such as prostate cancer, valued at USD 7.9 billion, and EGFR mutant non-small cell lung cancer, valued at USD 1.7 billion. Additionally, KROS 201 is developed for the treatment of glioblastoma. Customers and collaborators mentioned include Cedars-Sinai Medical Center, Janssen, and Pfizer.
Sources:
Kairos Pharma Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Kairos Pharma Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Kairos Pharma Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
